Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease

Detalhes bibliográficos
Autor(a) principal: Silva, Gilberto Marcelo Sperandio da
Data de Publicação: 2017
Outros Autores: Mediano, Mauro Felippe Felix, Hasslocher-Moreno, Alejandro Marcel, Holanda, Marcelo Teixeira de, Sousa, Andrea Silvestre de, Sangenis, Luiz Henrique Conde, Brasil, Pedro Emmanuel Alvarenga Americano do, Arteaga Mejía, Roger, Fux, Carina Perotti, Cubides, Juan Carlos, Saraiva, Roberto Magalhães, Brum-Soares, Lucia Maria
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/58601
Resumo: This study was supported by the international medical humanitarian organization Me´decins Sans Frontie`res (MSF) and the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil, Programa Estrate gico de Apoio a Pesquisa em Saude (Papes VII)/Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Brazil (grant 401878/ 2015–5 to G. S. d. S.).
id CRUZ_fc51bb7dadedc0701e22363ce66e5f48
oai_identifier_str oai:www.arca.fiocruz.br:icict/58601
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Silva, Gilberto Marcelo Sperandio daMediano, Mauro Felippe FelixHasslocher-Moreno, Alejandro MarcelHolanda, Marcelo Teixeira deSousa, Andrea Silvestre deSangenis, Luiz Henrique CondeBrasil, Pedro Emmanuel Alvarenga Americano doArteaga Mejía, RogerFux, Carina PerottiCubides, Juan CarlosSaraiva, Roberto MagalhãesBrum-Soares, Lucia Maria2023-05-24T01:39:30Z2023-05-24T01:39:30Z2017SILVA, Gilberto Marcelo Sperandio da et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease. Journal of Antimicrobial Chemotherapy, v. 72, n. 9, p. 2596-2601, Sept. 2017.0305-7453https://www.arca.fiocruz.br/handle/icict/5860110.1093/jac/dkx180This study was supported by the international medical humanitarian organization Me´decins Sans Frontie`res (MSF) and the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil, Programa Estrate gico de Apoio a Pesquisa em Saude (Papes VII)/Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Brazil (grant 401878/ 2015–5 to G. S. d. S.).Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Médecins Sans Frontières. Operational Center Barcelona. Barcelona, Spain.Médecins Sans Frontières. Operational Center Barcelona. Barcelona, Spain.Médecins Sans Frontières. Brazilian Medical Unit. Rio de Janeiro, RJ, Brazil.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Médecins Sans Frontières. Brazilian Medical Unit. Rio de Janeiro, RJ, Brazil.Background: Up to half of patients with Chagas’ disease under benznidazole treatment present adverse drug reactions (ADRs) and up to one-third do not complete standard treatment. Objectives: To verify the incidence and possible factors associated with the suspension of benznidazole treatment in a large cohort of patients. Methods: We included 2075 patients treated with benznidazole during the projects managed by the medical humanitarian organization Doctors Without Borders (Me´decins Sans Frontie`res) in Bolivia from 2009 to 2013. Benznidazole treatment was provided two or three times per day for 60 days at 5–7.5 mg/kg/day. A multiple logistic regression model was developed to evaluate the factors associated with permanent suspension of benznidazole treatment. Results: Permanent benznidazole treatment suspension occurred in 211 patients (10.2%) and the average time until permanent treatment suspension was 23 days. Multifactorial analysis revealed that female sex (adjusted OR " 1.70), moderate ADRs (adjusted OR " 10.57), mild ADRs (adjusted OR " 1.69) and skin disorders (adjusted OR " 4.18) were significantly associated with the permanent suspension of benznidazole treatment. Women with mild or moderate skin ADRs presented a probability of treatment interruption of 18.6% and 59.0%, respectively. Conclusions: Benznidazole treatment was safe and a large proportion of patients were able to complete a full course of benznidazole treatment under close treatment surveillance. Female sex, skin disorders and mild and moderate ADRs were independently associated with the permanent suspension of benznidazole treatment. In particular, women with moderate skin ADRs had the highest risk of benznidazole treatment interruption.engOxford University Presshttps://www.arca.fiocruz.br/handle/icict/34210Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleBenznidazoleMédecins Sans FrontièresBolivian patientsChagas diseaseinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALve_Gilberto_Silva_etal_INI_2017.pdfve_Gilberto_Silva_etal_INI_2017.pdfapplication/pdf142513https://www.arca.fiocruz.br/bitstream/icict/58601/2/ve_Gilberto_Silva_etal_INI_2017.pdfa3832e80b9dc620ffcf8eb2fb3ef1a68MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/58601/1/license.txt5a560609d32a3863062d77ff32785d58MD51icict/586012023-05-23 23:04:47.911oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-05-24T02:04:47Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
title Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
spellingShingle Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
Silva, Gilberto Marcelo Sperandio da
Benznidazole
Médecins Sans Frontières
Bolivian patients
Chagas disease
title_short Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
title_full Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
title_fullStr Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
title_full_unstemmed Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
title_sort Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease
author Silva, Gilberto Marcelo Sperandio da
author_facet Silva, Gilberto Marcelo Sperandio da
Mediano, Mauro Felippe Felix
Hasslocher-Moreno, Alejandro Marcel
Holanda, Marcelo Teixeira de
Sousa, Andrea Silvestre de
Sangenis, Luiz Henrique Conde
Brasil, Pedro Emmanuel Alvarenga Americano do
Arteaga Mejía, Roger
Fux, Carina Perotti
Cubides, Juan Carlos
Saraiva, Roberto Magalhães
Brum-Soares, Lucia Maria
author_role author
author2 Mediano, Mauro Felippe Felix
Hasslocher-Moreno, Alejandro Marcel
Holanda, Marcelo Teixeira de
Sousa, Andrea Silvestre de
Sangenis, Luiz Henrique Conde
Brasil, Pedro Emmanuel Alvarenga Americano do
Arteaga Mejía, Roger
Fux, Carina Perotti
Cubides, Juan Carlos
Saraiva, Roberto Magalhães
Brum-Soares, Lucia Maria
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Gilberto Marcelo Sperandio da
Mediano, Mauro Felippe Felix
Hasslocher-Moreno, Alejandro Marcel
Holanda, Marcelo Teixeira de
Sousa, Andrea Silvestre de
Sangenis, Luiz Henrique Conde
Brasil, Pedro Emmanuel Alvarenga Americano do
Arteaga Mejía, Roger
Fux, Carina Perotti
Cubides, Juan Carlos
Saraiva, Roberto Magalhães
Brum-Soares, Lucia Maria
dc.subject.en.en_US.fl_str_mv Benznidazole
Médecins Sans Frontières
Bolivian patients
Chagas disease
topic Benznidazole
Médecins Sans Frontières
Bolivian patients
Chagas disease
description This study was supported by the international medical humanitarian organization Me´decins Sans Frontie`res (MSF) and the Evandro Chagas National Institute of Infectious Diseases (INI) of the Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil, Programa Estrate gico de Apoio a Pesquisa em Saude (Papes VII)/Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Brazil (grant 401878/ 2015–5 to G. S. d. S.).
publishDate 2017
dc.date.issued.fl_str_mv 2017
dc.date.accessioned.fl_str_mv 2023-05-24T01:39:30Z
dc.date.available.fl_str_mv 2023-05-24T01:39:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv SILVA, Gilberto Marcelo Sperandio da et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease. Journal of Antimicrobial Chemotherapy, v. 72, n. 9, p. 2596-2601, Sept. 2017.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/58601
dc.identifier.issn.en_US.fl_str_mv 0305-7453
dc.identifier.doi.none.fl_str_mv 10.1093/jac/dkx180
identifier_str_mv SILVA, Gilberto Marcelo Sperandio da et al. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas’ disease. Journal of Antimicrobial Chemotherapy, v. 72, n. 9, p. 2596-2601, Sept. 2017.
0305-7453
10.1093/jac/dkx180
url https://www.arca.fiocruz.br/handle/icict/58601
dc.language.iso.fl_str_mv eng
language eng
dc.relation.uri.en_US.fl_str_mv https://www.arca.fiocruz.br/handle/icict/34210
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/58601/2/ve_Gilberto_Silva_etal_INI_2017.pdf
https://www.arca.fiocruz.br/bitstream/icict/58601/1/license.txt
bitstream.checksum.fl_str_mv a3832e80b9dc620ffcf8eb2fb3ef1a68
5a560609d32a3863062d77ff32785d58
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009289080471552

Registros relacionados